Mavorixafor
- Generic Name
- Mavorixafor
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27N5
- CAS Number
- 558447-26-0
- Unique Ingredient Identifier
- 0G9LGB5O2W
- Background
Mavorixafor is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Currently there is only one FDA-approved entry inhibitor, enfuvirtide (Fuzeon), that is available for the treatment of HIV infection. Several experimental entry inhibitors are now in early stage testing, including mavorixafor. Mavorixafor is a selective allosteric antagonist of the CXCR4 receptor on HIV, preventing the virus from entering and infecting healthy cells.
- Indication
Investigated for use/treatment in HIV infection.
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02680782
- Locations
- 🇺🇸
Covance CRU, Inc., Daytona Beach, Florida, United States
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT02667886
A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
- Conditions
- HIV InfectionsX4 Tropic Virus
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 10
- Registration Number
- NCT00361101
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
- First Posted Date
- 2004-08-06
- Last Posted Date
- 2021-11-09
- Target Recruit Count
- 6
- Registration Number
- NCT00089466
- Locations
- 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 44
- Registration Number
- NCT00063804
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.